MinervaX Announces Completion of Enrolment in Phase 1 Clinical Vaccine Trial as it Addresses the Global Burden of Group B Streptococcus in Older Adults
- Full enrolment and dosing commenced with its novel, prophylactic GBS vaccine in both healthy older adults and older adult population with co-morbidities
- First immunological read-outs are anticipated in Q4, 2023
Copenhagen, Denmark, 27 June 2023 – MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), has today announced the completion of enrolment and initial dosing in its Phase 1, clinical vaccine trial in older adults. The trial is taking place at CEVAC (Centre for Vaccinology), Ghent University, Belgium.
